# SIRT1

Source: https://onco.cc/targets/sirt1/  
OnCo record `sirt1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SIRT1 (NAD-dependent protein deacetylase sirtuin-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.

## Summary

NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metabolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively.

CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Niacinamide.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: sirtuin 1; NAD-dependent protein deacetylase sirtuin-1; SIR2L1
- Tags: cancer-genes-wave
- Symbol: SIRT1
- Class: transcription
- Biology: NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metabolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD(+)/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. Location: Nucleus, PML body; Cytoplasm; Nucleus; Nucleus, nucleoplasm (UniProt). Locus 10q21.3 (HGNC).
- Where found: Pancreatic ductal adenocarcinoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Pancreatic Ductal Carcinoma.

## Sources

- HGNC HGNC:14929: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14929
- UniProt Q96EB6: https://www.uniprot.org/uniprotkb/Q96EB6/entry
- NCBI Gene 23411: https://www.ncbi.nlm.nih.gov/gene/23411
- Ensembl ENSG00000096717: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000096717

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/sirt1.json